FDA Approves Belantamab Mafodotin-blmf for R/R Multiple Myeloma

Belantamab mafodotin-blmf (BLENREP®, GlaxoSmithKline) was recently FDA approved for adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have previously failed four therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Approval was based on DREAMM-2 (NCT03525678), an open-label, multicenter trial that enrolled 293 patients with R/R MM with disease progression after three or more lines of prior therapy and who were refr...
Continue reading

Osimertinib for EGFR-Mutated Advanced NSCLC: An Interview with Suresh S. Ramalingam, MD

The treatment of advanced-stage non-small cell lung cancer (NSCLC) has improved steadily in the past few years, and individualized therapy for patients with mutations in the epidermal growth factor receptor (EGFR) is applied in routine clinical practice. While EGFR-mutated NSCLC is effectively treated with tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, there is a need to develop more effective treatments to improve outcomes in these patients. In a study now published in The Ne...
Continue reading

Multiple Myeloma: DNA Translocation Creates Drug Resistance, Worsens Prognosis

​A new study reports that for patients with multiple myeloma, DNA translocation involving the immunoglobulin lambda (IgL) locus predicts poor outcomes and resistance to immunomodulatory imide drug (IMiD) therapies such as lenalidomide. The second most common hematological cancer, multiple myeloma has seen substantial increases in survival in recent years, thanks to a variety of new therapies. However, around 20% of patients still relapse or die within two years of diagnosis. Of these high-risk p...
Continue reading

The Impact of the FDA’s Revised Mammography Guidelines: Theresa W. Gillespie, PhD, MA, RN

For the first time in over 20 years, the FDA has proposed amendments to the Mammography Quality Standards Act (MQSA) in an effort to expand the information provided to patients and physicians, modernize standards for mammograms, and enable better enforcement of safety and quality regulations. In this interview with i3 Health, Theresa W. Gillespie, PhD, MA, RN, Professor at Emory University School of Medicine and at Emory's Winship Cancer Institute, discusses the significance of these changes and...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.